Belumosudil

If concomitant use cannot be avoided, decrease the CYP1A2 substrate dosage(s) in accordance with the respective Prescribing Information.

منبع: FDA openFDA

The serum concentration of Midazolam can be increased when it is combined with Belumosudil.

The risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with Belumosudil.

The risk or severity of adverse effects can be increased when 9-(N-methyl-L-isoleucine)-cyclosporin A is combined with Belumosudil.

The serum concentration of Belumosudil can be increased when it is combined with Abametapir.

The risk or severity of adverse effects can be increased when Abatacept is combined with Belumosudil.

The serum concentration of Abemaciclib can be increased when it is combined with Belumosudil.

The risk or severity of adverse effects can be increased when Abetimus is combined with Belumosudil.

Belumosudil may decrease the excretion rate of Acetyldigoxin which could result in a higher serum level.

The risk or severity of adverse effects can be increased when Acteoside is combined with Belumosudil.